Concepts (122)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Renal Cell | 7 | 2016 | 221 | 1.490 |
Why?
|
| Kidney Neoplasms | 8 | 2016 | 419 | 1.360 |
Why?
|
| Prostatic Neoplasms | 9 | 2021 | 1387 | 1.110 |
Why?
|
| Nephrectomy | 5 | 2016 | 157 | 1.030 |
Why?
|
| Prostatectomy | 6 | 2018 | 300 | 0.810 |
Why?
|
| Robotic Surgical Procedures | 4 | 2018 | 234 | 0.600 |
Why?
|
| Cryosurgery | 2 | 2016 | 51 | 0.550 |
Why?
|
| Lymph Node Excision | 2 | 2018 | 164 | 0.540 |
Why?
|
| Watchful Waiting | 1 | 2015 | 73 | 0.440 |
Why?
|
| Intraoperative Complications | 1 | 2014 | 155 | 0.400 |
Why?
|
| Urologic Surgical Procedures, Male | 1 | 2012 | 29 | 0.380 |
Why?
|
| Biomarkers, Tumor | 2 | 2015 | 1609 | 0.270 |
Why?
|
| Nomograms | 2 | 2015 | 37 | 0.220 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2024 | 1272 | 0.210 |
Why?
|
| Aged | 13 | 2024 | 20956 | 0.210 |
Why?
|
| Postoperative Complications | 2 | 2018 | 3113 | 0.200 |
Why?
|
| Biopsy | 3 | 2016 | 1241 | 0.200 |
Why?
|
| BCG Vaccine | 1 | 2024 | 110 | 0.200 |
Why?
|
| Aged, 80 and over | 7 | 2024 | 6783 | 0.170 |
Why?
|
| Middle Aged | 13 | 2024 | 28494 | 0.170 |
Why?
|
| Prostate-Specific Antigen | 4 | 2018 | 227 | 0.170 |
Why?
|
| Male | 16 | 2024 | 64669 | 0.150 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 566 | 0.150 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2024 | 492 | 0.150 |
Why?
|
| Patient Participation | 1 | 2021 | 246 | 0.150 |
Why?
|
| Neoplasm Grading | 2 | 2018 | 272 | 0.140 |
Why?
|
| Treatment Outcome | 8 | 2024 | 12908 | 0.140 |
Why?
|
| Retrospective Studies | 7 | 2016 | 17672 | 0.140 |
Why?
|
| Urination | 1 | 2017 | 24 | 0.130 |
Why?
|
| Lymphatic Metastasis | 2 | 2018 | 426 | 0.130 |
Why?
|
| Organ Size | 2 | 2015 | 425 | 0.120 |
Why?
|
| Kallikreins | 1 | 2015 | 26 | 0.120 |
Why?
|
| Prostatic Diseases | 1 | 2015 | 13 | 0.120 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2015 | 40 | 0.110 |
Why?
|
| Retroperitoneal Space | 1 | 2014 | 15 | 0.110 |
Why?
|
| Humans | 18 | 2024 | 130749 | 0.110 |
Why?
|
| Salvage Therapy | 1 | 2016 | 176 | 0.110 |
Why?
|
| Preoperative Period | 1 | 2014 | 91 | 0.110 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2015 | 51 | 0.110 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2015 | 179 | 0.110 |
Why?
|
| Radiation Dosage | 1 | 2014 | 136 | 0.100 |
Why?
|
| Age Distribution | 1 | 2014 | 426 | 0.100 |
Why?
|
| Lysophospholipids | 1 | 2013 | 39 | 0.100 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2013 | 68 | 0.100 |
Why?
|
| Disease Progression | 3 | 2015 | 2202 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2013 | 112 | 0.090 |
Why?
|
| Indoles | 1 | 2013 | 201 | 0.090 |
Why?
|
| Pyrroles | 1 | 2013 | 184 | 0.090 |
Why?
|
| Disease Management | 1 | 2015 | 563 | 0.090 |
Why?
|
| Carcinogenesis | 1 | 2013 | 351 | 0.080 |
Why?
|
| Cause of Death | 1 | 2012 | 512 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2016 | 2104 | 0.080 |
Why?
|
| Adult | 6 | 2016 | 31266 | 0.080 |
Why?
|
| Female | 8 | 2024 | 70618 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2015 | 5088 | 0.070 |
Why?
|
| Age Factors | 1 | 2014 | 2847 | 0.070 |
Why?
|
| Disease-Free Survival | 2 | 2024 | 904 | 0.070 |
Why?
|
| Prostate | 2 | 2007 | 408 | 0.070 |
Why?
|
| Prognosis | 1 | 2014 | 4933 | 0.060 |
Why?
|
| Administration, Intravesical | 1 | 2024 | 30 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 3869 | 0.050 |
Why?
|
| Urinalysis | 1 | 2024 | 73 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2003 | 137 | 0.050 |
Why?
|
| Patient Selection | 2 | 2018 | 722 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 1076 | 0.050 |
Why?
|
| Contrast Media | 2 | 2016 | 493 | 0.040 |
Why?
|
| Young Adult | 1 | 2014 | 10021 | 0.040 |
Why?
|
| Patient Preference | 1 | 2021 | 147 | 0.040 |
Why?
|
| Decision Support Techniques | 1 | 2021 | 297 | 0.040 |
Why?
|
| Risk Factors | 3 | 2018 | 11001 | 0.030 |
Why?
|
| Urodynamics | 1 | 2017 | 34 | 0.030 |
Why?
|
| Dissection | 1 | 2018 | 58 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2021 | 559 | 0.030 |
Why?
|
| Urinary Bladder Neck Obstruction | 1 | 2017 | 25 | 0.030 |
Why?
|
| Operative Time | 1 | 2018 | 207 | 0.030 |
Why?
|
| Decision Making | 1 | 2021 | 690 | 0.030 |
Why?
|
| Adolescent | 1 | 2014 | 20832 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2018 | 361 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2017 | 443 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2017 | 297 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2017 | 355 | 0.030 |
Why?
|
| Cell Dedifferentiation | 1 | 2015 | 21 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2016 | 350 | 0.030 |
Why?
|
| Time Factors | 2 | 2015 | 6240 | 0.030 |
Why?
|
| Urethral Obstruction | 1 | 2015 | 56 | 0.030 |
Why?
|
| Urography | 1 | 2014 | 20 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2024 | 5230 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2015 | 329 | 0.030 |
Why?
|
| Urology | 1 | 2015 | 80 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2014 | 226 | 0.020 |
Why?
|
| Microvessels | 1 | 2013 | 61 | 0.020 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2013 | 103 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2013 | 239 | 0.020 |
Why?
|
| Length of Stay | 1 | 2018 | 1398 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2013 | 708 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2015 | 828 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2016 | 1232 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 631 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2015 | 1512 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2013 | 975 | 0.020 |
Why?
|
| Body Weight | 1 | 2015 | 989 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 643 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2013 | 994 | 0.020 |
Why?
|
| Software | 1 | 2015 | 736 | 0.020 |
Why?
|
| Cell Movement | 1 | 2013 | 871 | 0.020 |
Why?
|
| Kidney | 1 | 2016 | 1285 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2013 | 814 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2017 | 6494 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2007 | 207 | 0.020 |
Why?
|
| Transcriptome | 1 | 2013 | 1128 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 3698 | 0.010 |
Why?
|
| Quality of Life | 1 | 2015 | 2089 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 4037 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2007 | 1387 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2003 | 155 | 0.010 |
Why?
|
| Risk | 1 | 2003 | 736 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2013 | 4668 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2003 | 1236 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2003 | 1307 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2007 | 1921 | 0.010 |
Why?
|
| Mice | 1 | 2013 | 18203 | 0.010 |
Why?
|
| Animals | 1 | 2013 | 33873 | 0.010 |
Why?
|